Navigation Links
SuperSonic Imagine Announces That Gordon Waldron Has Been Named Executive Vice President and CFO
Date:11/16/2010

AIX-EN-PROVENCE, France, Nov. 16, 2010 /PRNewswire/ -- SuperSonic Imagine, the innovative ultrasound medical imaging company, is pleased to announce Gordon Waldron has been named as Executive Vice President and CFO. As a member of the board of directors, he will be responsible for driving all of SuperSonic Imagine's key strategic and commercial partnerships as well as overseeing the company's financial development plan.

Prior to joining SuperSonic Imagine in September 2010, Mr. Waldron spent five years as CFO for the French biotech company Novexel where he raised 50 million euros in 2006, negotiated a preclinical license agreement which brought the company a 75 million euros upfront payment in 2008 and directed a trade sale process resulting in the acquisition of Novexel by AstraZeneca for cash consideration of approximately $500 million in 2009.

Before Novexel, he spent eight years as VP Finance with Synt:em (Nimes, France) where he raised 32 million euros in three financing rounds.

He also spent five years with Texas Instruments, first as Finance Director for a French subsidiary, then as Group Finance Manager (based in the UK) covering 17 entities and a distributor network for Texas Instruments Software in Europe, the Middle East and Africa.

Mr. Waldron started his career with Spie Batignolles at the Head Office near Paris before becoming a controller of the company's US subsidiaries based in Pittsburgh.

He graduated from Duke University (USA) in 1988 and has both American and British nationalities.

Mr. Waldron commented, "I am pleased to join such a high caliber group of people working in such an innovative environment. This mix has already produced some impressive R&D achievements as the company quickly differentiated itself through the creation of a software based ultrasound technology. The Aixplorer® MultiWave™ Ultrasound system not only offers exceptional image quality but also has the unique ability to provide tissue elasticity assessment which is fully reproducible and independent of the user's experience, skill and scanning technique. The next chapter will be to leverage this R&D excellence through commercial alliances and to extend applications for the Aixplorer platform from breast alone to multiple other organs."

SuperSonic Imagine Founder and CEO, Dr. Jacques Souquet (PhD.) remarked, "We have built a very strong management team at SuperSonic Imagine and having someone of Gordon's experience and stature enhances our capabilities. In today's global business environment and particularly in medical imaging, having the ability to drive strategic partnerships is critical. Gordon brings this and other know-how to the company and will be a great asset."

About SuperSonic Imagine:

Founded in 2005 and based in Aix-en-Provence, France, SuperSonic Imagine is an innovative, multinational medical imaging company dedicated to developing a revolutionary ultrasound system: the Aixplorer®. The system leverages a unique MultiWave™ technology that enables the user to detect, characterize and, in the future, treat palpable and non-palpable masses. Engineers from all over the world have joined the SuperSonic Imagine team and the company now has offices in Aix-en-Provence, Seattle, London and Munich. SuperSonic Imagine holds the exclusive rights to 25 international patients and submissions in diagnostic imaging and therapy applications that are solely owned and solely used by the company.

For further information about SuperSonic Imagine please visit our website: http://www.supersonicimagine.fr.   www.supersonicimagine.com


'/>"/>
SOURCE SuperSonic Imagine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):